TUSTIN, Calif., May 22 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), (http://www.amdl.com ), a world leader in specialty pharmaceuticals with operations in Shenzhen, Jiangxi and Jilin, China, announced today that it has made available the AMDL executive management comments from its Q1 2008 financial results conference call. The document can be accessed via AMDL's corporate website at http://www.amdl.com. Click on "Investor Relations" then "Recent News."
The posted conference call script outlines prepared remarks AMDL's
executive management made covering the Company's financial results for the
first quarter of FY2008 and the subsequent question and answers from
Highlighted comments from AMDL's CEO Gary Dreher included:
-- We have responded to the U.S. FDA regarding requests for information on
our DR-70(TM) cancer test within the time period required;
-- AMDL's executive management team is committed to increasing shareholder
communications, including formally issuing corporate guidance;
-- We are focused on growing annual sales at a minimum rate of 100 percent
over the next three years.
-- 2007 sales were $15 million and we are on track to at least doubling
sales in 2008;
-- AMDL will leverage its land holdings in China (estimated to be worth
between $15-$21 million) to gain a new credit facility in place by Q3,
-- We plan to finance continued growth with debt and credit lines. We do
not plan to pursue the same type of 25 percent discounted equity
funding as we've done in previous rounds;
-- AMDL's anti-aging Goodnak product line is enjoying high growth demand
and we anticipate it will be exported to the US and Europe in the
-- AMDL's head of R&D Dr. Andrea Small-Howard has conclud
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved